- |||||||||| prasinezumab (RG7935) / Roche, mesdopetam (IRL790) / Ipsen, tavapadon (CVL-751) / Cerevel Therap
NEW INSIGHT IN THE TREATMENT OF PARKINSONS DISEASE (ONSITE - HALL F1+F2+F3) - Dec 23, 2022 - Abstract #ADPD2023ADPD_877; The PASADENA study tested prasinezumab and despite the primary end-point was not met positive signals were seen...The ORCHESTRA study with UCB0059, an oral Asyn antibody is also ongoing...A new dopamine agonist, tavapadon. Two different studies on dyskinesia are ongoing with a combination of buspirone and zolmitriptan and another with mesdopetam.
- |||||||||| levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Journal: Brivaracetam or levetiracetam in status epilepticus?: Lessons from the photosensitivity model. (Pubmed Central) - Dec 18, 2022 This modified design allows one to monitor the time to CNS effect (i.e., PPR elimination) of a quickly-acting FDA-approved ASM given i.v., a crucial element in status epilepticus treatment. This paper was presented at the 8th London-Innsbruck Colloqium on Status Epilepticus and Acute Seizures held in September 2022.
- |||||||||| Journal: Cytochrome P450-mediated antiseizure medication interactions influence apoptosis, modulate the brain BAX/Bcl-X ratio and aggravate mitochondrial stressors in human pharmacoresistant epilepsy. (Pubmed Central) - Dec 16, 2022
We divided the patients into groups-those who took combinations of NON-CYP + CYP substrate ASMs, NON-CYP + CYP inducer ASMs, CYP substrate + CYP substrate or CYP substrate + CYP inducer ASMs-to study the 1) pro- and anti-apoptotic protein levels and other apoptotic signaling proteins and levels of reactive oxygen species (reduced glutathione and lipid peroxidation) in brain tissues; 2) cytotoxicity at blood-brain barrier epileptic endothelial cells (EPI-ECs) and subsequent changes in mitochondrial membrane potential in normal neuronal cells, following treatment with LCM + OXC (CYP substrate + CYP inducer) or LCM + LEV (CYP substrate + NON-CYP-substrate) after blood-brain barrier penetration, and 3) apoptotic and mitochondrial protein targets in the cells, pre-and post-CYP3A4 inhibition by ketoconazole and drug treatments...Together, the study highlights for the first time that pro- and anti-apoptotic proteins levels are dependent on ASM combinations in epilepsy, modulated via a CYP-mediated mechanism that controls free radicals, cytotoxicity and mitochondrial activity. These findings lead to a better understanding of future drug selection choices offsetting pharmacodynamic CYP-mediated interactions.
- |||||||||| levetiracetam / Generic mfg.
PK/PD data, Journal: Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy. (Pubmed Central) - Dec 12, 2022 Based on PBPK predictions, the recommended dose of levetiracetam is 1.2, 1.6, and 1.5 times the baseline dose in the first, second, and third trimesters, respectively, not exceeding 4000 mg/day in the third trimester due to fetal safety. The levetiracetam PBPK model for pregnancy was successfully developed and validated, and could provide alternative levetiracetam dosing regimens across the stages of pregnancy.
- |||||||||| levetiracetam / Generic mfg.
Review, Journal: Potential risk of liver injury in epileptic patients during COVID-19 pandemic. (Pubmed Central) - Dec 10, 2022 Intravenous form of levetiracetam which has no significant hepatic metabolism or drug-drug interaction is often a favorable option to control seizures in acute phase of COVID-19...In patients with epilepsy who receive polytherapy with ASMs, transient dose modification with the tendency to increase the dose of ASMs with more favorable safety profile and less drug interaction and decrease the dose of drugs with main hepatic metabolism, high protein binding, potential to cause liver injury and known drug-drug reaction should be considered. Finally, decision making should be individualized based on patients' conditions and course of illness.
- |||||||||| Seizalam (midazolam intramuscular) / Pfizer
Review, Journal: Focal status epilepticus: a review of pharmacological treatment. (Pubmed Central) - Dec 6, 2022 The available scientific evidence is insufficient to claim that pharmacological treatment of focal SE should be different from treatment for generalised SE. More studies with a greater number of patients are needed.
- |||||||||| Journal: Cerebrovascular accident in a child with precursor B-cell acute lymphoblastic leukemia and coronavirus disease 2019: a case report. (Pubmed Central) - Dec 6, 2022
This new method offers improvements for chiral molecule quantification in complex multicomponent chiral systems and can be applied to other chiral spectroscopy techniques. Owing to the link between coronavirus disease 2019 and hematologic cancers with hypercoagulopathy and the tendency of patients with leukemia to have coronavirus disease 2019 complications, children with leukemia as well as suspected coronavirus disease 2019 must be hospitalized to prevent blood clot formation.
- |||||||||| levetiracetam / Generic mfg., oxcarbazepine / Generic mfg.
Retrospective data, Journal: Effects of new antiseizure medication on bone metabolism and bone mineral density in children: A meta-analysis. (Pubmed Central) - Dec 3, 2022 However, the effects of new antiseizure medication on serum calcium and bone alkaline phosphatase in children were not statistically significant. New antiseizure medication have different effects on bone metabolism and bone mineral density in children with epilepsy, and the effects of different types of new antiseizure medication are different.
- |||||||||| dexamethasone / Generic mfg., clonazepam / Generic mfg., levetiracetam / Generic mfg.
Journal: Myoclonus status revealing COVID 19 infection. (Pubmed Central) - Nov 30, 2022 We believe that there is an inflammatory process involved with increased levels of proinflammatory cytokines and systemic inflammation, including cytokine storm or cytokine release syndrome targeting the brain and more specifically the cortex and basal ganglia [6]. Data collection in clinical registries is needed to increase our knowledge of the prevalence of neurological symptoms in patients with COVID-19 and will hopefully clarify the causal relationship between SARS-CoV-2 infection and post-COVID-19 myoclonic syndrome.
- |||||||||| Akineton (biperiden) / Endo, AbbVie
Preclinical, Journal: Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines. (Pubmed Central) - Nov 30, 2022 Results showed that levetiracetam, valproic acid, and haloperidol were able to induce a relevant synergistic antitumor effect when associated with the chemotherapy currently used in clinic (temozolomide)...Fingolimod appeared to have anoikis-related cell death. Thus, the assayed drugs which are able to cross the blood-brain barrier could represent a possibility to improve the treatment of neural tumors, though future in vivo studies and clinical trials will be necessary to validate it.
- |||||||||| Opdivo (nivolumab) / Ono Pharma, BMS
Posterior Reversible Encephalopathy Syndrome: A Rare Side Effect of Nivolumab () - Nov 29, 2022 - Abstract #ASH2022ASH_7828; He was started on steroids along with 500 mg Keppra twice a day...He was discharged and started on Fluorouracil, Folinic Acid, Oxaliplatin (FOLFOX) chemotherapy as outpatient for possible upper gastrointestinal (GI) cancer...He was started on a high dose of prednisone, 1mg/kg/day along with 20 mg lisinopril for strict blood pressure control with a goal of 120/80 mmHg...Recommendations are to avoid fluctuations in blood pressure with a goal of 130-150/80-100mmHg. If any triggering factor or condition is identified like immunotherapy, it should be avoided or treated accordingly.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study () - Nov 29, 2022 - Abstract #ASH2022ASH_7332; Twenty-nine (87 %) patients received levetiracetam for seizure-prophylaxis.MRD was measured after each cycle by RT-qPCR with a sensitivity of 10-4 for clonal IgH and for BCR-ABL.As MRD response was considered clonal IgH or BCR-ABL < 10-4.Relapse-free survival (RFS) and overall survival (OS) were estimated by the Kaplan-Meier analysis and compared by the log-rank across the sub-groups using 95 % confidence intervals...MRD-responsive gain a significant survival advantage over non-responsive patients. This advantage was observed both for transplanted and non-transplanted patients.
- |||||||||| lacosamide / Generic mfg., lorazepam / Generic mfg., levetiracetam / Generic mfg.
Refractory Acute Symptomatic Seizures in Critically Ill Adults from a Multicenter Cohort Study (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1908; Apart from electro-clinical findings like convulsive ASyS, status epilepticus and EAs on cEEG, we found that underlying etiology independently predicts the development of refractory ASyS. These findings could inform future clinical trials investigating ASyS treatment.
- |||||||||| levetiracetam / Generic mfg.
Clinical Charicteristics of Newly Diagnosed Adolescent Onset Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1893; A good outcome for adolescent-onset epilepsy can generally be expected in the short term. Our data will improve our understanding of adolescent-onset epilepsy and assist in treatment.
- |||||||||| levetiracetam / Generic mfg., clobazam / Generic mfg., ethosuximide / Generic mfg.
Serial EEG Patterns and Treatment Regimen Choices in Patients with Syngap 1 (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1833; EEG patterns involve diffuse cortical regions with generalized epileptic patterns on serial EEG studies with little variation of type of Syngap1 mutation. ASM have no clear effect on EEG patterns over time.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Neurologic and Obstetrical Outcomes in Pregnant Women with Epilepsy After Craniotomy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1781; The cesarian section rate of 48% is higher than the national average of 31.9%, though in this study over half of cesarian sections were planned due to previous cesarian sections or due to craniotomy history. Women who delivered vaginally had no acute neurologic complications.
- |||||||||| levetiracetam / Generic mfg.
Valproate or levetiracetam for Juvenile Myoclonic Epilepsy? (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1776; Our results show the superiority of VPA vs. LEV treatment in JME. Woman of chilbearing potential should be counseled regularly regarding the relative risk and benefits of valproate.
- |||||||||| levetiracetam / Generic mfg.
Levetiracetam Intravenous Push in Elderly Patients () - Nov 29, 2022 - Abstract #AES2022AES_1652; In the future, the MONEAD study will assess cognitive and behavior at age 6 yo. In agreement with prior reports in adult patients, our findings suggest that rapid administration of undiluted IVP LEV doses up to 3000 mg is well-tolerated and safe with proper monitoring in elderly patients, including those aged 75 years old or above.
- |||||||||| levetiracetam / Generic mfg.
Characteristics Predictive of Suicidal Ideation in Adolescents with Focal Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1557; Suicidality in this group is likely multifactorial, with contributions from the underlying CNS disease, ASM side effects, and psychosocial factors. Our findings emphasize the critical need for prompt diagnosis and the importance of mental health evaluation in guiding the comprehensive care of youth with new-onset epilepsy.
- |||||||||| levetiracetam / Generic mfg.
Epilepsy Management in US Nursing Homes (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1438; Interestingly families/guardians are more likely to request transfer to hospitals than what physicians feel necessary. Our study demonstrates and acknowledges the absence of standard practices for treatment of epilepsy across NHs and lays the foundation for development of educational programs for NH physicians, staff, and families.
- |||||||||| lacosamide / Generic mfg., levetiracetam / Generic mfg., topiramate / Generic mfg.
Comparison of Antiseizure Medications as Monotherapy in Focal and Generalized Epilepsy (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1400; LTG was found to have the highest rate and duration of seizure freedom in patients with generalized as well as focal epilepsy. Although limited by a small sample size, our study demonstrated a high rate and duration of seizure freedom with lacosamide for some patients with focal epilepsy as well.
- |||||||||| levetiracetam / Generic mfg., clobazam / Generic mfg.
Review of EEG Abnormalities and Epilepsy in scl6a1-related Disorder (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1347; We demonstrated that generalized abnormalities on EEG were more common than focal features. Further, absence epilepsy was more prevalent than myoclonic atonic seizures, and IRDA on EEG was common.
- |||||||||| Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Long-term Effect of Cenobamate in a Cohort of Therapy Refractory Adult Patients with Different Types of Epilepsies (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1344; The comedication was lamotrigine (49), valproate (41), clobazam (35), brivaracetam/levetiracetam (37), lacosamide (15), oxcarbazepine (15), perampanel (7), zonisamide (5), stiripentol (5), topiramate (4), phenobarbital (2), rufinamide (1), felbamate (1), carbamazepine (1). Overall, adjunct CNB has been found to be generally safe and effective for treatment-resistant seizures in adult pts, a few therapy-resistant pts got seizure free and the retention rate, a mixture of effect and side effects was 91.4% after 6 months.
- |||||||||| Epilepsy Prevalence in the Veterans Health Administration (Hall B, Level 3) - Nov 29, 2022 - Abstract #AES2022AES_1272;
Similarly, as topiramate is linked to teratogenicity, providers should communicate this risk with all potential patients of child-bearing age. Continuous surveillance of epilepsy patients in the VHA is vital for optimal care and appropriate allocation of resources.
|